10/09/2026 US FDA granted Priority Review to Roche’s Enspryng for MOGAD US FDA granted Priority Review to Roche’s Enspryng for MOGAD. (Ref) Roche announced that the US FDA had granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab; anti- IL-6) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The filing acceptance was based on positive results from the Phase 3, METEOROID study, whi